Expression of the cytoplasmic tail of LMP1 in mice induces hyperactivation of B lymphocytes and disordered lymphoid architecture

Immunity

Volumn 21, Issue 2, 2004, Pages 255-266

  Stunz, Laura L ^c,d   Busch, Lisa K ^a,d   Munroe, Melissa E ^c,d   Sigmund, Curt D ^a,c,d   Tygrett, Lorraine T ^c,d   Waldschmidt, Thomas J ^b,c,d   Bishop, Gail A ^a,b,c,d,e  

^a Molecular Biology Graduate Program   (United States)

^b Immunology Graduate Program   (United States)

^c Department of Microbiology ^*  (United States)

^d UNIVERSITY OF IOWA   (United States)

^e VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CD40 ANTIGEN; INTERLEUKIN 6; LATENT MEMBRANE PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY AFFINITY; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; B LYMPHOCYTE ACTIVATION; BREED; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOPLASM; DENDRITIC CELL; GENETIC ENGINEERING; GERMINAL CENTER; IMMUNIZATION; LYMPHADENOPATHY; LYMPHOCYTE SUBPOPULATION; LYMPHOID CELL; MACROPHAGE; MOUSE; MOUSE STRAIN; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; SPLENOMEGALY; TRANSGENIC MOUSE; VIRUS INFECTION;

ANIMALS; ANTIBODY FORMATION; ANTIGENS, CD40; AUTOIMMUNITY; B-LYMPHOCYTES; EPSTEIN-BARR VIRUS INFECTIONS; FLUORESCENT ANTIBODY TECHNIQUE; HYPERSENSITIVITY; IMMUNOGLOBULINS; INTERLEUKIN-6; LYMPHOCYTE ACTIVATION; MICE; SIGNAL TRANSDUCTION; SPLEEN; VIRAL MATRIX PROTEINS;

EID: 4143124227     PISSN: 10747613     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.immuni.2004.07.008     Document Type: Article

References (59)

1. Aarden L.A., de Groot E.R., Feltkamp T.E. Immunology of DNA. III. Crithidia luciliae, a simple substrate for the determination of anti-dsDNA with the immunofluorescence technique. Ann. N Y Acad. Sci. 254:1975;505-515
2. Ardila-Osorio H., Clausse B., Mishal Z., Wiels J., Tursz T., Busson P. Evidence of LMP1-TRAF3 interactions in glycosphingolipid-rich complexes of lymphoblastoid and nasopharyngeal carcinoma cells. Int. J. Cancer. 81:1999;645-649
3. Baccam M., Bishop G. Membrane-bound CD154, but not CD40-specific antibody, mediates NF-kappaB-independent IL-6 production in B cells. Eur. J. Immunol. 29:1999;3855-3866
4. Baccam M., Woo S., Vinson C., Bishop G. CD40-mediated transcriptional regulation of the IL-6 gene in B Lymphocytes. involvement of NF-kB, AP-1, and C/EBP J. Immunol. 170:2003;3099-3108
5. Bishop G., Hostager B. B lymphocyte activation by contact-mediated interactions with T lymphocytes. Curr. Opin. Immunol. 13:2001;278-285
6. Bishop G., Warren W., Berton M. Signaling via MHC class II molecules and antigen receptors enhances the B cell response to gp39/CD40L. Eur. J. Immunol. 25:1995;1230-1238
7. Brown K., Hostager B., Bishop G. Differential signaling and TRAF degradation mediated by CD40 and the EBV oncoprotein LMP1. J. Exp. Med. 193:2001;943-954
8. Brown K., Hostager B., Bishop G. Regulation of TRAF2 signaling by self-induced degradation. J. Biol. Chem. 277:2002;19433-19438
9. Busch L., Bishop G.A. The EBV transforming protein, LMP1, mimics and cooperates with CD40 signaling in B lymphocytes. J. Immunol. 162:1999;2555-2561
10. Busch L., Bishop G. Multiple carboxyl-terminal regions of the EBV oncoprotein, LMP1, cooperatively regulate signaling to B lymphocytes via TRAF-dependent and TRAF-independent mechanisms. J. Immunol. 167:2001;5805-5813
11. Campbell I., Hamilton J., Wicks I. Collagen-induced arthritis in C57BL/6 (H-2b) mice. new insights into an important disease model of RA Eur. J. Immunol. 30:2000;1568-1575
12. Devergne O., Hatzivassiliou E., Izumi K., Kaye K., Kleijnen M., Kieff E., Mosialos G. Association of TRAF1, TRAF2, and TRAF3 with an EBV LMP1 domain important for B-lymphocyte transformation. role in NF-kB activation Mol. Cell. Biol. 16:1996;7098-7108
13. Eliopoulos A., Stack M., Dawson C., Kaye K., Hodgkin L., Sihota S., Rowe M., Young L. EBV-encoded LMP1 and CD40 mediate IL-6 production in epithelial cells via an NF-kB pathway involving TRAFs. Oncogene. 14:1997;2899-2916
14. Fennewald S., van Santen V., Kieff E. Nucleotide sequence of an mRNA transcribed in latent growth-transforming virus infection indicates that it may encode a membrane protein. J. Virol. 51:1984;411-419
15. Foy T., Aruffo A., Bajorath J., Buhlmann J., Noelle R. Immune regulation by CD40 and its ligand GP39. Annu. Rev. Immunol. 14:1996;591-617
16. Foy T., Laman J., Ledbetter J., Aruffo A., Claassen E., Noelle R. gp39-CD40 interactions are essential for GC formation and the development of B cell memory. J. Exp. Med. 180:1994;157-163
17. Foy T., Shepherd D., Durie F., Aruffo A., Ledbetter J., Noelle R. In vivo CD40-gp39 interactions are essential for TD humoral immunity. II. Prolonged suppression of the humoral immune response by an Ab to the ligand for CD40, gp39. J. Exp. Med. 178:1993;1567-1575
18. Hardy R., Hayakawa K. B cell development pathways. Annu. Rev. Immunol. 19:2001;595-621
19. He B., Raab-Traub N., Casali P., Cerutti A. EBV-encoded LMP1 cooperates with BAFF/BLyS and APRIL to induce T cell-independent Ig heavy chain class switching. J. Immunol. 171:2003;5215-5224
20. Horton R.M. PCR-mediated recombination and mutagenesis. SOEing together tailor-made genes. Mol. Biotechnol. 3:1995;93-99
21. Hostager B., Catlett I., Bishop G. Recruitment of CD40 and TRAFs 2 and 3 to membrane microdomains during CD40 signaling. J. Biol. Chem. 275:2000;15392-15398
22. Hsing Y., Bishop G. Requirement for NF-kB activation by a distinct subset of CD40-mediated effector functions in B lymphocytes. J. Immunol. 162:1999;2804-2811
23. Huen D., Henderson S., Croom-Carter D., Rowe M. The EBV LMP1 mediates activation of NF-kB and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene. 10:1995;549-560
24. Ishida T., Mizushima S., Azuma S., Kobayashi N., Tojo T., Suzuki K., Aizawa S., Watanabe T., Mosialos G., Kieff E., et al. Identification of TRAF6, a novel TRAF protein that mediates signaling from an amino-terminal domain of the CD40 cytoplasmic region. J. Biol. Chem. 271:1996;28745-28748
25. Ishihara K., Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev. 13:2002;357-368
26. Izumi K.M., Kieff E.D. The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-kappaB. Proc. Natl. Acad. Sci. USA. 94:1997;12592-12597
27. Jacob J., Kassir R., Kelsoe G. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. I. The architecture and dynamics of responding cell populations. J. Exp. Med. 173:1991;1165-1175
28. Jalukar S., Hostager B., Bishop G. Characterization of the roles of TRAF6 in CD40-mediated B lymphocyte effector functions. J. Immunol. 164:2000;623-630
29. James J., Harley J. B-cell epitope spreading in autoimmunity. Immunol. Rev. 164:1998;185-200
30. Kawabe T., Naka T., Yoshida K., Tanaka T., Fujiwara H., Suematsu S., Yoshida N., Kishimoto T., Kikutani H. The immune responses in CD40-deficient mice. impaired Ig class switching and GC formation Immunity. 1:1994;167-178
31. Kaye K.M., Izumi K., Kieff E. EBV LMP1 is essential for B-lymphocyte growth transformation. Proc. Natl. Acad. Sci. USA. 90:1993;9150-9154
32. Kiberd B. IL-6 receptor blockage ameliorates murine lupus nephritis. J. Am. Soc. Nephrol. 4:1993;58-61
33. Kilger E., Kieser A., Baumann M., Hammerschmidt W. EBV-mediated B-cell proliferation is dependent upon LMP1, which simulates an activated CD40 receptor. EMBO J. 17:1998;1700-1709
34. Kouskoff V., Fehling H.J., Lemeur M., Benoist C., Mathis D. A vector driving the expression of foreign cDNAs in the MHC class II-positive cells of transgenic mice. J. Immunol. Methods. 166:1993;287-291
35. Kozak M. Point mutations define a sequence flanking the AUG initiator codon that modulates translation by eukaryotic ribosomes. Cell. 44:1986;283-292
36. Kulwichit W., Edwards R., Davenport E., Baskar J., Godfrey V., Raab-Traub N. Expression of the EBV LMP1 induces B cell lymphoma in transgenic mice. Proc. Natl. Acad. Sci. USA. 95:1998;11963-11968
37. Kurzrock R. Cytokine deregulation in cancer. Biomed. Pharmacother. 55:2001;543-547
38. Liebowitz D., Wang D., Kieff E. Orientation and patching of the latent infection membrane protein encoded by EBV. J. Virol. 58:1986;233-237
39. Long E., Rosen-Bronson S., Karp D., Malnati M., Sekaly R., Jaraquemada D. Efficient cDNA expression vectors for stable and transient expression of HLA-DR in transfected fibroblast and lymphoid cells. Hum. Immunol. 31:1991;229-235
40. Lorenz H., Herrmann M., Kalden J. The pathogenesis of autoimmune diseases. Scand. J. Clin. Lab. Invest. 235:2001;16-26
41. Lutz M., Kukutsch N., Ogilvie A., Rossner S., Koch F., Romani N., Schuler G. An advanced culture method for generating large quantities of highly pure dendritic cells from mouse BM. J. Immunol. Methods. 223:1999;77-92
42. Luzina I., Atamas S., Storrer C., daSilva L., Kelsoe G., Papadimitriou J., Handwerger B. Spontaneous formation of GC in autoimmune mice. J. Leukoc. Biol. 70:2001;578-584
43. Marai I., Gilburd B., Blank M., Shoenfeld Y. Anti-cardiolipin and anti-beta2-glycoprotein I (beta2GP-I) Ab assays as screening for anti-phospholipid syndrome. Hum. Antibodies. 12:2003;57-62
44. Mosialos G., Birkenbach M., Yalamanchili R., VanArsdale T., Ware C., Kieff E. The EBV transforming protein LMP1 engages signaling proteins for the TNFR family. Cell. 80:1995;389-399
45. Nishimoto N., Sasai M., Shima Y., Nakagawa M., Matsumoto T., Shirai T., Kishimoto T., Yoshizaki K. Improvement in Castleman's disease by humanized anti- IL-6 receptor Ab therapy. Blood. 95:2000;56-61
46. Pasare C., Medzhitov R. Toll pathway-dependent blockade of CD4+CD25+ T cell-mediated suppression byDC. Science. 299:2003;1033-1036
47. Rhodus N. Sjogren's syndrome. Quintessence Int. 30:1999;689-699
48. Rolink A., Schaniel C., Andersson J., Melchers F. Selection events operating at various stages in B cell development. Curr. Opin. Immunol. 13:2001;202-207
49. Sandberg M., Hammerschmidt W., Sugden B. Characterization of LMP-1's association with TRAF1, TRAF2, and TRAF3. J. Virol. 71:1997;4649-4656
50. Schiffer L., Hussain N., Wang X., Huang W., Sinha J., Ramanujam M., Davidson A. Lowering anti-dsDNA antibodies - what's new? Lupus. 11:2002;885-894
51. Schultheiss U., Puschner S., Kremmer E., Mak T.W., Engelmann H., Hammerschmidt W., Kieser A. TRAF6 is a critical mediator of signal transduction by the viral oncogene LMP1. EMBO J. 20:2001;5678-5691
52. Shoenfeld Y. Etiology and pathogenetic mechanisms of the anti-phospholipid syndrome unraveled. Trends Immunol. 24:2003;2-4
53. Takahashi Y., Dutta P., Cerasoli D., Kelsoe G. In situ studies of the primary immune response to (4-hydroxy-3-nitrophenyl)acetyl. V. Affinity maturation develops in two stages of clonal selection. J. Exp. Med. 187:1998;885-895
54. Tang B., Matsuda T., Akira S., Nagata N., Ikehara S., Hirano T., Kishimoto T. Age-associated increase in IL-6 in MRL/lpr mice. Int. Immunol. 3:1991;273-278
55. Uchida J., Yasui T., Takaoka-Shichijo Y., Muraoka M., Kulwichit W., Raab-Traub N., Kikutani H. Mimicry of CD40 signals by EBV LMP1 in B lymphocyte responses. Science. 286:1999;300-303
56. Waldschmidt T., Panoskaltsis-Mortari A., McElmurry R.T., Tygrett L., Taylor P.A., Blazar B. Abnormal TD B-cell responses in SCID mice receiving allogeneic BM in utero. Severe combined immune deficiency. Blood. 100:2002;4557-4564
57. Wan J., Sun L., Mendoza J., Chui Y., Huang D., Chen Z., Suzuki N., Suzuki S., Yeh W.C., Akira S., et al. Elucidation of the c-Jun N-terminal kinase pathway mediated by EBV-encoded LMP1. Mol. Cell. Biol. 24:2004;192-199
58. Wang D., Liebowitz D., Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell. 43:1985;831-840
59. Xie P., Hostager B., Bishop G. Requirement for TRAF3 in signaling by LMP1 but not CD40 in B Lymphocytes. J. Exp. Med. 199:2004;661-671